Tudor Investment Corp ET AL Takes Position in Liquidia Corporation $LQDA

Tudor Investment Corp ET AL acquired a new stake in shares of Liquidia Corporation (NASDAQ:LQDA) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 67,557 shares of the company’s stock, valued at approximately $1,536,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Liquidia by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after purchasing an additional 1,700 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Liquidia by 10.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after purchasing an additional 82,955 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Liquidia by 15.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after buying an additional 16,022 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Liquidia by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,405,747 shares of the company’s stock worth $17,517,000 after buying an additional 32,499 shares in the last quarter. Finally, Creative Planning lifted its holdings in shares of Liquidia by 40.7% in the second quarter. Creative Planning now owns 26,840 shares of the company’s stock valued at $334,000 after buying an additional 7,765 shares during the period. Institutional investors own 64.54% of the company’s stock.

Liquidia Stock Performance

Shares of NASDAQ LQDA opened at $35.03 on Monday. The stock’s fifty day simple moving average is $37.64 and its 200 day simple moving average is $31.88. The stock has a market capitalization of $3.09 billion, a price-to-earnings ratio of -42.20 and a beta of 0.52. The company has a quick ratio of 1.84, a current ratio of 2.01 and a debt-to-equity ratio of 2.97. Liquidia Corporation has a 52-week low of $11.26 and a 52-week high of $46.67.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. The business had revenue of $92.02 million during the quarter, compared to analyst estimates of $87.49 million. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The company’s revenue for the quarter was up 3072.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.

Insider Activity at Liquidia

In other Liquidia news, insider Jason Adair sold 688 shares of the firm’s stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $41.65, for a total value of $28,655.20. Following the completion of the transaction, the insider directly owned 211,169 shares in the company, valued at $8,795,188.85. This trade represents a 0.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Scott Moomaw sold 18,314 shares of Liquidia stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $36.79, for a total transaction of $673,772.06. Following the completion of the transaction, the insider directly owned 187,640 shares in the company, valued at approximately $6,903,275.60. This trade represents a 8.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 230,848 shares of company stock valued at $8,638,491. Corporate insiders own 26.50% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on LQDA shares. Wall Street Zen raised Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a report on Thursday, January 22nd. Needham & Company LLC raised their price objective on shares of Liquidia from $52.00 to $54.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Wells Fargo & Company lifted their price objective on shares of Liquidia from $44.00 to $51.00 and gave the stock an “overweight” rating in a research note on Monday, March 23rd. Finally, HC Wainwright boosted their target price on shares of Liquidia from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $43.44.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).